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1  | INTRODUCTION
Routine haemostasis testing and determination of coagulation fac-
tors are influenced by many pre- analytical variables. These variables 
include sample collection, sample processing, sample storage con-
ditions (whole blood, centrifuged plasma maintained in the original 
sodium citrate tube or aliquoted centrifuged plasma), storage time 
and temperature, reagents and system used to analyse the sample. 
Understanding the potential impact of these variables on laboratory 
results is of great importance. Results affected by pre- analytical errors 
can have a significant impact on patient outcomes, such as diagnosis 
or treatment.1-4 The Clinical and Laboratory Standards Institute (CLSI) 
guidelines (Document H21- A5) state that whole blood samples or 
plasma samples, stored at room temperature (RT), for routine haemo-
stasis tests or determination of coagulation factors should be analysed 
within 4 hours after sample collection, with exception of prothrombin 
time (PT) testing with stability up to 24 hours.5 However, for many 
coagulation parameters, acceptance of a longer storage time at RT is 
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Abstract
Introduction: Haemostasis testing is influenced by many pre- analytical variables, such 
as storage time and temperature, which can affect the stability of coagulation factors 
and influence the results of coagulation assays. We investigated the stability of hae-
mostasis tests after storage of aliquoted plasma at RT, including the variability of 
measurement principle and reagent used for determination.
Methods: Blood samples from 20 healthy volunteers were obtained, processed to PPP 
and aliquoted. Aliquots were stored at RT for 0 hour, 2 hours, 4 hours, 6 hours, 
8 hours, 12 hours, 24 hours and 48 hours. PT, aPTT, fibrinogen, D-Dimers and coagu-
lation factors (FII, FV, FVII, FX, FVIII, FIX, FXI, FXII) were determined by STA- R Max® 
and ACL- TOP®. VWF:Ag and vWF:RCo were determined by AcuStar®. Clinically rele-
vant changes, compared to the initial measurement, were denoted as a percentage 
change of > 10% according to the 99% CI.
Results: For both analysers, a clinically relevant change of > 10% was observed for FV 
after 2 hours, FVIII after 4 hours and for aPTT, FII, FVII, FX and FXII after 48 hours of 
storage at RT. Statistically significant, but no clinically relevant differences were ob-
served after 48- hours storage for PT, fibrinogen and FIX. D- Dimers, FXI, vWF:Ag and 
vWF:RCo were found stable up to 48 hours at RT.
Conclusion: Overall, compared to the limits given by the current CLSI guidelines, for 
most coagulation parameters investigated in this study a longer storage period could 
be accepted. Time intervals for FVIII and FV dosage were shorter than recommended 
by the CLSI guidelines. For PT determination, our findings were consistent.
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described.6-15 This information can be interesting, for example, when 
additional coagulation tests are requested or when laboratories have 
to outsource coagulation tests to a laboratory at distance from the 
place of sample collection.
The aim of this study was to investigate the stability of haemostasis 
tests after storage of aliquoted plasma samples at room temperature 
for different time periods and to evaluate whether a longer storage 
period is acceptable compared with the current CLSI guidelines.5 We 
based our recommendations on the clinically relevant change, further 
defined in materials and method and following the criteria of Zürcher 
et al6 Also, the influence of using different measurement principles 
and reagents on the stability of coagulation parameters was investi-
gated using two different haemostasis analysers with corresponding 
reagents.
2  | MATERIALS AND METHODS
2.1 | Sample collection and processing
Plasma samples of 20 healthy volunteers (11 men and 9 women; 
between the age of 22 and 46 years) were collected. All volunteers 
agreed to sample collection for this study and signed an informed 
consent. Sample collection of healthy volunteers was approved 
by the Ethical Committee of the Ghent University Hospital. From 
each volunteer, 16 citrate tubes (BD Vacutainer®, New Jersey, 
USA) of 2.7 mL were collected. Due to the high number of citrate 
tubes needed per volunteer, blood collection was performed with a 
winged blood sample set (Terumo® Europe NV, Louvain, Belgium). 
Sample collection of all volunteers was performed in the laboratory, 
so no transportation of the samples was needed, and centrifugation 
of the citrate tubes could take place within 10 minutes after blood 
collection.
For the determination of routine coagulation parameters (PT, 
activated partial thromboplastin time (aPTT), fibrinogen and D- 
Dimers), a single centrifugation at RT of 15 minutes at 1500 g was 
performed. Platelet- poor plasma (PPP) was immediately separated. 
Per volunteer, PPP of all collected citrate tubes was pooled to avoid 
tube-tube variability. Pooled plasma was aliquoted in Eppendorf 
cups (Bioscience Inc., Salt Lake City, USA), immediately sealed 
after aliquotation and stored for different storage periods (0 hour, 
2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours) at 
RT. Routine parameters were measured on fresh (nonfrozen) plasma 
in parallel on both analysers.
For determination of intrinsic factors (FVIII, FIX, FXI and FXII), 
extrinsic factors (FII, FV, FVII and FX), von Willebrand factor antigen 
(vWF:Ag) and von Willebrand factor ristocetin cofactor activity (vW-
F:RCo), the pooled PPP was centrifuged a second time for 15 minutes 
at 1500 g at RT. Supernatant was separated immediately after centrif-
ugation and aliquoted into Eppendorf cups. Aliquots were immediately 
sealed after aliquotation, stored for different storage periods (0 hour, 
2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours) at RT 
and frozen at −20°C. Before testing, the frozen plasma aliquots were 
thawed for 5 minutes in a water bath of 37°C and then vortexed.
2.2 | Analysers and reagents
PT, aPTT, fibrinogen, D- Dimers and coagulation factors (FVIII, FIX, FXI, 
FXII, FII, FV, FVII and FX) were determined by STA- R Max® (Diagnostica 
Stago®, S.A.S., France) using a viscosity- based principle and corre-
sponding Stago® reagents and by ACL- TOP® 350CTS (Instrumentation 
Laboratory, Werfen, Bedford, USA) using a turbidimetric measure-
ment principle and corresponding HemosIL® reagents. VWF:Ag and 
vWF:RCo were determined by AcuStar® (Instrumentation Laboratory) 
using a chemiluminescent technique and corresponding HemosIL® rea-
gents. APTT and PT determined by STA- R Max® were both analysed by 
2 different reagents. For measurement of aPTT and PT by ACL- TOP®, 
1 reagent was used. All reagents used in this study are listed in Table 1
For each parameter and each analyser, the between- run coeffi-
cients of variation (CV), calculated by the runs performed in this study, 
are given in Table 1.
2.3 | Statistical analysis
Data are presented as median with a corresponding interquartile range 
(IQR) for each storage period. Because not all data sets showed a nor-
mal distribution, the analysis of variance, between various time intervals 
of a given assay, was performed by a nonparametric assay, namely the 
Friedman repeated measure analysis of variance. A P- value <.05 denotes 
a statistically significant difference. When the Friedman test shows a sig-
nificant difference, separate Wilcoxon signed rank tests with Bonferroni 
adjustment were performed, as post hoc test, to examine statistically sig-
nificant differences compared to the control group (time 0 hour).
In addition, the percentage change between the initial measured 
value and subsequent storage periods was calculated, using formula 
below:
Percentage changes are presented as mean percentage change 
with a corresponding 99% confidence interval (99% CI) for each stor-
age period. The 99% CI for the percentage change was calculated using 
the following equation based on the criteria used by Zürcher et al6: 
t0.01 is the percentage point of the t- distribution with (n- 1) degrees 
of freedom which gives a two- tailed probability of 1% and SEM is the 
standard error of the mean.6
Finally, a change in the coagulation assay value compared with the 
initial measurement of > 10% according to the 99% CI was defined as 
a clinically relevant difference. All statistical analyses were performed 
with IBM® SPSS® Statistics version 24.
We based our recommendations of acceptable storage time at RT 
on the percentage change according to the 99% CI compared to the 
initial measurement. For coagulation factors, we mainly focused on a 
clinically relevant decline to make an interpretation about the possible 
acceptable storage time at RT.
%Changet=x=
Resultt=x−Resultt=0
Resultt=0
×100
Mean%change± (t0.01×SEM)
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3  | RESULTS
For PT values determined by STA®- Neoplastine R and HemosIL® 
ReadiPlasTin, a percentage change of more than 10% compared with 
the initial results (time 0 hour) is observed according to the 99% CI 
after 48- hours storage, when PT values are given in percentage (STA®- 
Neoplastine R 99% CI: - 11.4% to - 5.9%; HemosIL® ReadiPlasTin 99% 
CI: - 11.4% to - 6.9%). For PT values expressed in seconds or INR, per-
centage changes are less than 10% after 48 hours of storage at RT for 
all 3 PT reagents used (Table 2).
A statistically significant increase in aPTT is seen after 6- hours 
storage of plasma at RT for all 3 aPTT reagents used, with a percent-
age increase compared to baseline values less than 10% according to 
the 99% CI. For aPTT measured by STA®- Cephascreen and HemosIL®, 
a 24- hours storage period at RT shows a percentage change of less 
than 10% according to the 99% CI, which can be considered as not 
clinically relevant. However for aPTT values measured by STA®- PTT 
automate, a 99% CI of 8.0% to 10.7% is seen after 24- hours storage. 
An increase of more than 10% compared to initial results is seen after 
48- hours storage at RT for all 3 aPTT reagents (STA®- PTT Automate 
99% CI: 11.7% to 14.5%; STA®- Cephascreen 99% CI: 9.2% to 12.3%; 
HemosIL® SynthASil 99% CI: 9.0% to 11.1%, Table 2). This prolonga-
tion of aPTT is mainly due to a significant reduction of FVIII activity 
with a mean percentage decline of 38.5% and 35.8% for Stago® and 
HemosIL®, respectively, after 48- hours storage at RT.
A 4- hours storage period at RT shows a statistically and clin-
ically significant difference of FVIII activity with a mean percentage 
decrease of more than 10% for both Stago® and HemosIL® reagents 
(Table 3). However, for FVIII values measured by Stago®, a 99% CI of 
- 10.9% to 6.7% is seen after 2 hours of storage at RT, which can be 
considered as clinically relevant. The other clinically relevant intrinsic 
coagulation factors—FIX and FXI—remain stable for at least 48 hours, 
as shown in Table 3. A significant increase of FXII activity is seen at 48- 
hours storage, with a mean percentage increase of 13.9% and 10.3% 
for Stago® and HemosIL®, respectively. For Stago®, a 99% CI of - 2.4 to 
11.4 was observed at a storage time of 12 hours at RT, suggesting an 
acceptable storage time of 8 hours at RT.
While mean percentage changes of FV activity for both Stago® and 
HemosIL® are less than 10% after a storage period of 2 hours at RT, 
the 99% CI shows a possible decline of more than 20% (Table 3). A 
percentage decline of > 10% of FV activity after 2- hours storage at RT 
is observed in 36% and 43% of the samples for Stago® and HemosIL®, 
respectively.
A significant decline of FVII activity, determined by HemosIL®, 
is observed at 24- hours storage with a mean percentage change of 
- 7.0% (99% CI of - 13.3% to - 0.7%). For both HemosIL® and Stago®, 
a significant decrease in FVII activity is seen at 48- hours storage, but 
FVII determined by HemosIL® shows a more distinct decrease com-
pared to Stago® (mean percentage change: - 9.5% and - 21.1% for 
Stago® and HemosIL®, respectively).
FII and FX remain stable up to 24 hours of storage at RT. After a 
storage period of 48 hours, a statistically and clinically significant de-
cline is observed for both coagulation factors (Table 3).
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TABLE  3 Coagulation factors by STA- R Max® and ACL- TOP®
FVIII (Stago® Diagnostics) FVIII (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 94.3 19 75.5 to 112.6 97.7 19 82.1 to 128.5
2 90.8 20 75.8 to 115.1 − 2.1** − 10.9 to 6.7 94 20 74.6 to 125.1 − 1.8 − 8.7 to 5.7
4 77.6* 20 54.9 to 109.8 − 14.9** − 30.2 to 0.4 82.4* 20 61.9 to 115.3 − 10.7** − 18.4 to 2.9
6 75.4* 20 58.0 to 110.3 − 13.9** − 33.0 to 5.2 81.1* 20 61.0 to 106.2 − 11.3** − 24.2 to 1.3
8 70.4* 20 57.3 to 88.8 − 21.8** − 34.0 to − 9.5 83.6* 20 61.5 to 111.3 − 11.6** − 23.7 to 0.4
12 74.2* 20 51.0 to 99.4 − 20.1** − 33.8 to − 6.5 83.5* 20 60.6 to 109.5 − 13.2** − 24.5 to − 1.8
24 67.5* 20 42.8 to 80.2 − 33.6** − 44.9 to − 22.3 68.1* 20 46.3 to 83.9 − 31.3** − 41.6 to − 21.0
48 56.8* 20 43.9 to 80.3 − 38.5** − 49.7 to − 27.2 61.3* 20 43.1 to 79.2 − 35.8** − 46.0 to − 25.6
P- value Friedman <.001 <.001
FIX (Stago® Diagnostics) FIX (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 113.6 19 95.9 to 121.7 110.8 19 99.2 to 127.6
2 115.2 20 99.1 to 127.1 − 0.2 − 3.7 to 3.3 110.8 19 98.2 to 125.0 − 0.8 − 3.5 to 1.8
4 113.1 20 102.0 to 
128.2
1.6 − 2.1 to 5.4 110.8 20 96.5 to 128.9 − 1.6 − 3.5 to 0.3
6 119.2 20 98.4 to 126.6 1.9 − 2.6 to 6.5 110.8 20 96.5 to 132.8 − 0.6 − 3.6 to 2.5
8 105.4* 19 96.8 to 122.0 − 3.7 − 7.0 to − 0.4 107.5 20 97.3 to 130.2 − 1.1 − 4.8 to 2.7
12 109.5 19 98.8 to 122.3 − 1.0 − 5.9 to 3.9 110.3 20 97.5 to 127.6 − 1.1 − 4.5 to 2.2
24 110.4 20 94.8 to 121.7 − 2.6 − 6.9 to 1.8 106.4* 20 93.4 to 126.0 − 5.2 − 8.2 to − 2.2
48 111.8 19 99.7 to 121.5 − 3.3 − 8.6 to 1.9 104.3* 19 90.6 to 122.5 − 5.6 − 9.2 to − 2.0
P- value Friedman .004 <.001
FXI (Stago® Diagnostics) FXI (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 110.9 19 97.0 to 112.9 116.8 19 99.5 to 127.2
2 110.4 20 97.0 to 138.1 − 1.0 − 5.6 to 3.6 112.4 19 99.5 to 137.3 − 0.3 − 7.2 to 6.6
4 113.5 19 99.3 to 132.7 0.1 − 3.1 to 3.2 114.6 20 97.4 to 133.6 − 3.2 − 5.8 to − 0.6
6 111.4 20 97.9 to 147.5 0.5 − 3.5 to 4.2 113.5 20 99.5 to 128.4 − 2.5 − 5.3 to 0.2
8 108.9 19 100.9 to 
130.2
− 3.0 − 7.9 to 1.9 111.4 19 101.3 to 124.8 − 1.2 − 4.7 to 2.2
12 107.6 20 99.9 to 127.3 − 2.6 − 7.1 to 1.9 114.1 20 100.0 to 131.9 − 3.3 − 6.6 to 0.1
24 109.5 20 96.1 to 126.6 − 3.4 − 8.0 to 1.2 112.5 20 101.6 to 129.1 − 3.4 − 6.8 to 0.0
48 108.7 19 97.2 to 129.9 − 3.2 − 8.8 to 2.3 113.5 19 98.5 to 128.4 − 2.9 − 6.2 to 0.4
P- value Friedman .395 .290
FXII (Stago® Diagnostics) FXII (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 89.0 19 74.6 to 114.4 124.9 18 95.5 to 158.3
2 85.5 19 73.6 to 109.6 − 0.9 − 4.8 to 3.0 114.0 18 97.7 to 152.7 − 0.7 − 4.3 to 2.9
4 83.2 19 73.1 to 110.8 − 2.0 − 8.1 to 4.1 128.4 19 94.0 to 163.8 1.2 − 3.8 to 6.3
(Continues)
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FXII (Stago® Diagnostics) FXII (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
6 86.0 19 71.2 to 112.7 − 1.1 − 6.4 to 4.2 117.6 19 98.1 to 156.5 0.1 − 3.4 to 3.5
8 86.8 20 74.5 to 115.9 − 0.7 − 6.3 to 5.0 117.6 19 97.3 to 152.3 0.1 − 5.4 to 5.6
12 88.2 19 77.1 to 117.5 4.3** − 2.9 to 11.4 116.5 19 97.3 to 155.1 2.9 − 3.9 to 9.8
24 91.3 19 79.4 to 115.8 6.7** − 0.5 to 13.8 119.1 18 97.1 to 148.3 3.3 − 0.9 to 7.5
48 94.5* 18 83.7 to 120.1 13.9** 6.1 to 21.7 122.9* 18 102.7 to 157.5 10.3** 3.7 to 17.0
P- value 
Friedman
<.001 <.001
FII (Stago® Diagnostics) FII (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 99.1 14 78.2 to 109.8 106.8 14 99.3 to 120.8
2 99.1 18 72.0 to 106.4 − 2.6 − 8.8 to 3.7 106.8 16 102.6 to 116.7 2.9 − 1.7 to 7.5
4 99.7 15 75.8 to 107.0 − 2.0 − 7.6 to 3.6 115.9 14 99.3 to 124.3 4.3** − 2.8 to 11.5
6 102.1 17 76.8 to 109.7 0.6 − 2.8 to 4.0 108.2 17 97.3 to 115.9 0.6 − 3.9 to 5.1
8 100.9 18 75.8 to 111.6 2.0 − 3.4 to 7.5 105.3 17 96.1 to 119.2 0.4 − 5.4 to 6.2
12 101.9 19 75.1 to 108.4 − 2.7 − 7.8 to 2.4 106.8 18 97.3 to 120.8 1.3 − 5.5 to 8.2
24 103.0 17 73.5 to 108.8 − 2.3 − 6.0 to 1.4 105.3 17 96.1 to 115.9 − 1.6 − 8.0 to 4.9
48 97.8* 18 70.7 to 109.1 − 6.7** − 16.3 to 
2.8
97.3* 18 93.7 to 109.0 − 7.6** − 12.9 to − 2.3
P- value 
Friedman
.196 <.001
FV (Stago® Diagnostics) FV (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 71.1 14 53.8 to 76.6 78.3 14 71.2 to 96.1
2 70.6 19 49.5 to 81.7 − 4.8** − 22.0 to 12.3 74.2 16 61.7 to 93.2 − 8.9** − 20.0 to 2.2
4 68.2 15 55.3 to 84.4 − 8.0** − 23.3 to 7.4 72.7 14 62.9 to 90.6 − 11.8** − 28.4 to 4.7
6 71.0 17 51.5 to 80.8 − 4.8** − 25.9 to 16.3 72.7 16 58.7 to 87.5 − 7.1** − 27.8 to 13.7
8 73.1 18 55.8 to 85.7 − 6.1** − 19.0 to 6.7 77.4 18 63.6 to 85.7 − 10.2** − 29.5 to 9.0
12 59.7 19 39.1 to 87.5 − 13.7** − 33.9 to 6.4 75.0 18 58.5 to 94.0 − 10.1** − 37.6 to 17.4
24 66.4 17 51.6 to 91.6 − 12.4** − 30.2 to 5.4 64.2 17 57.5 to 89.0 − 18.9** − 41.2 to 3.3
48 67.1 17 49.0 to 82.9 − 3.6** − 21.2 to 14.1 75.8 18 62.0 to 86.1 − 8.4** − 32.9 to 16.0
P- value 
Friedman
.629 .605
FVII (Stago® Diagnostics) FVII (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 93.7 14 64.4 to 106.1 93.6 13 84.2 to 109.2
2 90.2 18 67.5 to 105.0 0.7 − 5.9 to 7.2 90.2 16 79.2 to 101.3 − 3.4 − 6.4 to − 0.3
4 95.1 15 75.3 to 106.0 3.1** − 5.1 to 11.4 97.4 14 82.4 to 122.2 5.4** − 2.9 to 13.8
6 93.6 17 76.2 to 110.7 4.2** − 1.6 to 10.1 101.3 17 85.8 to 105.5 − 0.3 − 8.2 to 7.7
(Continues)
TABLE  3  (Continued)
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For fibrinogen levels measured by HemosIL® Q.F.A. Thrombin, a 
statistically significant decline is observed at 48 hours of storage at 
RT; however according to the percentage change (99% CI: - 9.5% to 
- 3.5%), as shown in Table 4, it can be considered as not clinically rel-
evant. VWF:Ag as well as vWF:RCo measured by AcuStar® remain 
stable up to 48 hours at RT. No statistically significant differences (P- 
value Friedman: .748 and .159 for vWF:Ag and vWF:RCo, respectively) 
nor clinically relevant changes were observed. After 48- hours storage 
at RT, mean percentage changes of 2.7% (99% CI: - 1.0% to 6.3%) and 
- 2.3% (99% CI: - 6.2% to 2.2%) were seen for vWF:Ag and vWF:RCo, 
respectively.
In this study, only healthy volunteers were included, so only low 
D- Dimer values are observed (baseline results range from 0.011 μg/
mL to 0.600 μg/mL with a median of 0.258 μg/mL for STA®- Liatest 
and from 0.034 μg/mL to 0.587 μg/mL with a median of 0.117 μg/mL 
for HemosIL® HS 500). Because of these low values, high percentage 
changes were seen; therefore, it was decided not to use percentage 
changes to evaluate the stability of D- Dimers. For volunteers with 
baseline D- Dimer values below the upper normal range (0.500 μg/mL), 
no increase of D- Dimer results above the reference interval was seen 
during storage, except for 1 volunteer who had a baseline  D- Dimer 
value near the upper normal range. No statistically significant differ-
ences between the baseline values and results after storage at RT 
up to 48 hours were observed (P- value Friedman: .548 and .089 for 
STA®- Liatest and HemosIL® HS 500, respectively).
4  | DISCUSSION
Storage conditions, storage time and temperature are some of the 
many variables that can affect the stability of coagulation factors and 
influence the results of coagulation assays.1-4 We studied the stability 
of aliquoted plasma samples stored at RT for up to 48 hours. Several 
studies have investigated the stability of coagulation parameters, 
mainly routine haemostasis parameters, in different storage condi-
tions7-10,13,16; however, information regarding the stability of coagula-
tion factors studied for up to 48 hours is scarce.6
According to our knowledge, no published guidelines, defining 
acceptable percentage changes for clinically relevant difference com-
pared with baseline values, are available.12,14 In this study, we denoted 
FVII (Stago® Diagnostics) FVII (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
8 91.4 17 73.8 to 110.0 3.4 − 0.3 to 7.2 102.7 17 87.4 to 111.5 3.4 − 1.9 to 8.4
12 90.0 19 68.9 to 108.9 2.0 − 5.8 to 9.8 96.1 18 80.4 to 103.4 − 3.0 − 9.2 to 3.3
24 87.3 17 73.3 to 103.5 − 2.0 − 8.2 to 4.2 92.4 17 77.8 to 101.3 − 7.0** − 13.3 to − 0.7
48 81.5* 18 66.5 to 97.5 − 9.5** − 19.7 to 0.7 76.9* 18 69.6 to 86.5 − 21.1** − 25.3 to − 17.0
P- value 
Friedman
.002 <.001
FX (Stago® Diagnostics) FX (HemosIL®)
Activity (%) Change vs 0 h (%) Activity (%) Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 90.1 14 75.5 to 106.7 101.9 14 86.7 to 123.3
2 89.0 17 71.3 to 109.0 − 2.0 − 6.1 to 2.1 96.2 16 87.5 to 114.1 0.3 − 2.4 to 3.0
4 92.6 15 72.7 to 106.5 − 2.8 − 8.3 to 2.7 104.8 14 91.0 to 119.5 1.1 − 1.6 to 3.8
6 95.2 17 73.7 to 110.4 − 1.0 − 5.4 to 3.4 108.4 17 91.3 to 118.2 0.3 − 3.3 to 3.9
8 94.6 18 78.7 to 109.0 1.0 − 5.4 to 7.4 96.2 17 86.8 to 114.8 − 0.3 − 3.8 to 3.2
12 96.6 19 67.4 to 106.8 − 3.4 − 9.9 to 3.0 99.4 18 86.3 to 117.8 − 1.3 − 4.8 to 2.2
24 94.8 17 69.1 to 106.9 − 3.7 − 8.2 to 0.9 92.2 17 83.8 to 114.1 − 3.4 − 7.7 to 1.0
48 89.0* 18 59.3 to 100.5 − 8.4** − 18.1 to 1.3 92.5* 18 82.8 to 111.9 − 7.0** − 10.8 to − 3.1
P- value 
Friedman
.106 <.001
CI, confidence interval; IQR, interquartile range.
*denotes a statistically significant difference (P < .05) compared with the control group (time 0 h) following Wilcoxon signed rank tests with Bonferroni 
adjustments.
**denotes a potentially clinically significant difference (> 10%) of the 99% CI for the percentage change compared with the control group (time 0 h).
TABLE  3  (Continued)
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a clinically relevant change as a percentage change of > 10% according 
to the 99% CI, following the criteria used by Zürcher et al6 To justify 
the use of this arbitrary chosen percentage change in our study and 
to make sure that the analytical imprecision does not have a greater 
impact on the results than the changes due to storage time, between- 
run coefficient of variation (CV) was calculated for all parameters. All 
between- run CV’s were less 8.5% (Table 1).
Several studies, including ours, observed a stability of 24 hours 
for PT determination of samples stored at RT,6,9,10,12,13 confirming 
the storage time given by the current CLSI guidelines. After 48- hours 
to 52- hours storage at RT, Zürcher et al6 observed a mean percent-
age decrease of 10.8%. In our study, according to the 99% CI, we 
showed a clinically relevant decrease for PT expressed in percentage 
after 48- hours storage. However, PT determinations expressed in 
INR or seconds appear to be stable up to 48 hours at RT. Also, fibrin-
ogen test results were found to be stable for up to 48 hours stored 
at RT, in line with the observations of Zürcher et al6 As expected, 
also in our study, a prolongation of aPTT was observed during stor-
age at RT. However, we confirmed a stability up to 12 hours to 
24 hours (depending on the aPTT reagent used) observed by some 
TABLE  4 Fibrinogen analysis by STA- R Max® and ACL- TOP®
Fibrinogen (STA®- Liquid- Fib) Fibrinogen (HemosIL® Q.F.A. Thrombin)
Clauss mg/dL Change vs 0 h (%) Clauss mg/dL Change vs 0 h (%)
Time (h) Median n IQR Mean (99% CI) Median n IQR Mean (99% CI)
0 325 20 266 to 360 314 20 250 to 364
2 328 20 254 to 373 − 0.8 − 4.6 to 3.0 300 20 251 to 375 0.2 − 2.8 to 3.1
4 334 20 265 to 372 0.2 − 3.5 to 3.8 302 20 247 to 360 − 0.2 − 2.1 to 1.8
6 333 20 268 to 368 1.2 − 2.0 to 4.3 304 20 246 to 258 0.7 − 1.9 to 3.2
8 332 20 275 to 371 2.3 − 1.0 to 5.7 302 20 245 to 258 − 1.3 − 3.6 to 1.0
12 335 20 268 to 379 1.0 − 2.7 to 4.7 302 20 246 to 258 − 0.2 − 2.6 to 2.3
24 316 20 267 to 373 − 0.9 − 4.9 to 3.0 296 20 243 to 348 − 2.0 − 4.1 to 0.1
48 320 20 272 to 370 0.0 − 4.4 to 4.4 275* 20 234 to 339 − 6.5 − 9.5 to − 3.5
P- value Friedman .254 <.001
CI, confidence interval; IQR, interquartile range.
*denotes a statistically significant difference (P < .05) compared with the control group (time 0 h) following Wilcoxon signed rank tests with Bonferroni 
adjustments. **denotes a potentially clinically significant difference (> 10%) of the 99% CI for the percentage change compared with the control group (time 
0 h).
Coagulation assay
Acceptable storage time at RT 
(CLSI H21 A5)
Acceptable storage time at 
RT (our findings)*
aPTT 4 h 12 h- 24 h
PT 24 h 24 h- 48 h
Fibrinogen 4 h 48 h
D- Dimers 4 h 48 h
FVIII 4 h < 2 h- 2 h
FIX 4 h 48 h
FXI 4 h 48 h
FXII 4 h 8 h- 24 h
FII 4 h 24 h
FV 4 h < 2 h
FVII 4 h 12 h- 24 h
FX 4 h 24 h
vWF:Ag and vWF:RCo 4 h 48 h
aPTT, activated partial thromboplastin time; CLSI, Clinical and Laboratory Standards institute; PT, pro-
thrombin time; RT, room temperature; vWF:Ag, von Willebrand factor antigen; vWF:RCo, von 
Willebrand factor ristocetin cofactor activity.
*Percentage change > 10% compared to baseline results according to the 99% confidence interval was 
noted as a clinically relevant change.
TABLE  5 Comparison of the acceptable 
storage at room temperature according to 
the CLSI guidelines5 and according to our 
study findings
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studies.6,9 In contrast, other studies illustrated an aPTT stability of 
6 hours13 and 8 hours10,12,14 at RT. These discrepant findings may be 
due to different study populations or to the use of different aPTT 
reagents.17,18 Although differences in results between the aPTT re-
agents used in this study were small, for STA®- PTT Automate, a clin-
ically relevant elevation was observed after 24- hours storage, while 
aPTT measurements by the other 2 reagents were stable for up to 
24 hours at RT. The differences in stability results of FVII activity 
in our study might also be due to the difference in PT reagent used 
for analysis. Measurements by Stago® showed a clinically relevant 
FVII decline after 48- hours storage, while for HemosIL® reagents, 
the loss of FVII activity was already relevant after 24- hours storage 
at RT. Due to the different origin of thromboplastin used in the PT 
reagents, factor dosage, especially FVII, may be influenced.17
FVIII and FV are both known to be labile coagulation factors. A 
rapid decline of both factor activities is observed in our study, with a 
stability up to 2 hours for FVIII measured by HemosIL® and even less 
than 2 hours for FV. The poor stability of FVIII is illustrated by several 
studies with a 23- 26.9% loss of FVIII activity after 24- hours storage 
at RT6,8,10 and acceptable storage periods of 2 hours,10 < 3 hours19 
and < 4 hours.6 As FVIII is important for diagnosis of haemophilia A, 
differentiation of von Willebrand disease and thrombophilia screen-
ing, strict pre- analytical conditions for FVIII determination should be 
defined in every laboratory. However, for FV, we do not confirm the 
findings of several studies demonstrating a stability of FV activity up to 
8 hours,16 12 hours6 and 24 hours.8 In our study, percentage changes 
of > 10% were observed even after 2 hours storage at RT for FV mea-
surements by both analysers. We do not have a solid explanation for 
these discrepant findings, but it has to be pointed out that our study 
investigated stability in aliquoted plasma, while in most other studies, 
stability was investigated after storage of whole citrated blood. Due to 
the loss of the haemoglobin buffering capacity, processed samples are 
more sensitive to a pH change than whole blood samples, and inacti-
vation of mainly FVIII and FV is enhanced.3,14
The increase in FXII activity, observed in our study after a stor-
age time of 12 hours for Stago® and 48 hours for HemosIL®, might 
be due to contact activation as is described for plasma samples 
stored refrigerated.20 For FII, FIX, FX, FXI, vWF:Ag and vWF:RCo, a 
stability of 24 hours8 even up to 48 hours6 is described. Feng et al10 
however observed a clinically relevant reduction of FIX activity for 
plasma stored up to 6 hours at 4°C as well as 25°C and presents an 
acceptable time interval of 4 hours for FIX determination. While we 
confirm the 48- hours stability for FIX, FXI, vWF:Ag and vWF:RCo, 
in our study, a clinically relevant decline of FII and FX activity was 
observed after 48- hours storage. Consequently, for FII and FX de-
terminations, we recommend a storage time of 24 hours at RT as 
more acceptable.
Looking back, inclusion of some samples with borderline D- Dimer 
values or high D- Dimer values (above 0.500 μg/mL) would have given 
us more information about the stability of D- Dimer. D- Dimer testing is 
mostly used for excluding deep venous thrombosis or pulmonary em-
bolism in patients with levels below the predefined cut- off (0.500 μg/
mL).21 D- Dimer levels decreasing during extended storage could give 
false- negative values and change the clinical decision- making. In this 
study, we could not investigate false negativity because only 1 volun-
teer had a D- Dimer baseline value above the cut- off.
Some other limitations of this study should be mentioned. In this 
study, the stability data are limited as we did not explore samples from 
patients receiving heparin or vitamin K antagonists, but only from 
healthy volunteers, especially for aPTT and PT. Also in our experimen-
tal setting, only aliquoted plasma was stored at RT, which in a hospi-
tal setting can be interesting, for example for additional test requests. 
However, as we did not research the stability of haemostasis tests after 
storage of whole blood or plasma on packed cells at RT, our data are 
mainly applicable to our study conditions. As it was not possible for all 
aliquots to be measured by both haemostasis analysers for all coagula-
tion factors, we were limited in comparing the results of the 2 analysers.
In conclusion, when compared to the limits given by the current 
CLSI guidelines (H21- A5 2008),5 our observations are consistent for PT 
determination. The time interval for FVIII and FV dosage was shorter 
than recommended in the CLSI guidelines. For all other parameters in-
vestigated in this study, the stability period given by the CLSI guidelines 
is too stringent. A summarizing table of the acceptable storage time at 
RT according to the current CLSI guidelines vs our findings is given in 
Table 5.
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